Please wait while the formulary information is being retrieved.
HEMABATE (CARBOPROST TROMETHAMINE)
- Abortion
- Postpartum hemorrhage
250 mcg/mL intramuscular solution
- Inject 250 mcg by intramuscular route initially, the dosage being repeated every 1.5-3.5 hours depending on uterine response
Abortion
- Inject 250 mcg by intramuscular route initially, the dosage being repeated every 1.5-3.5 hours depending on uterine response
Cervical ripening procedure
- Inject 250 mcg by intramuscular route initially, the dosage being repeated every 1.5-3.5 hours depending on uterine response
Incomplete abortion
- Inject 250 mcg by intramuscular route initially, the dosage being repeated every 1.5-3.5 hours depending on uterine response
Induction of labor
- Inject 250 mcg by intramuscular route initially, the dosage being repeated every 1.5-3.5 hours depending on uterine response
Postpartum hemorrhage
- Inject 250 mcg by intramuscular route initially, if necessary the dosage may be repeated at 15-90 minute intervals on the basis of response
- None
Contraindicated
- None
Severe
Moderate
- None
- Inflammatory disease of female pelvic organs
- Pregnancy- third trimester
Contraindicated
- Cardiac disease
- Disease of liver
- Kidney disease with reduction in GFR
- Pulmonary disease
Severe
Moderate
- Anemia
- Asthma
- Diabetes mellitus
- Hypertension
- Hypotension
- Seizure disorder
HEMABATE (CARBOPROST TROMETHAMINE)
- Abortion
- Postpartum hemorrhage
- None
- Cough
- Diarrhea
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- None
- Abdominal pain with cramps
- Back pain
- Blepharospasm
- Blurred vision
- Chest tightness
- Chills
- Dizziness
- Epistaxis
- Fever
- Flushing
- Headache disorder
- Hiccups
- Hyperhidrosis
- Mastalgia
- Myalgias
- Nervousness
- Paresthesia
- Polydipsia
- Sleep disorder
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Allergic dermatitis
- Anaphylaxis
- Angioedema
- Bradycardia
- Bronchospastic pulmonary disease
- Chest pain
- Dyspnea
- Hypertension
- Injection site sequelae
- Paralytic ileus
- Peripheral vasoconstriction
- Skin rash
- Tachycardia
- Wheezing
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Carboprost tromethamine
No established safety and efficacy in pediatrics.
- 1 Day – 18 Years
- No established safety and efficacy in pediatrics.
Carboprost Tromethamine
- Severity Level:
1
- Additional Notes: Fda c;drug is oxytocic,not for use during normal gestation
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Carboprost
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Abortion | |
| Z33.2 | Encounter for elective termination of pregnancy |
| Postpartum hemorrhage | |
| O72 | Postpartum hemorrhage |
| O72.1 | Other immediate postpartum hemorrhage |
| 0-9 | A-Z |
|---|---|
| O72 | Postpartum hemorrhage |
| O72.1 | Other immediate postpartum hemorrhage |
| Z33.2 | Encounter for elective termination of pregnancy |
Formulary Reference Tool